Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM
NCT ID: NCT05129774
Last Updated: 2021-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
40 participants
INTERVENTIONAL
2022-01-01
2027-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
radical surgery with PALND
Radical surgery with PALND
sufficient resection margins of the tumor, D3 dissection of the regional lymph nodes and para-aortic lymph node dissection from the bifurcation of iliac artery to the left renal vein via laparoscopic approach
radical surgery without PALND
Radical surgery without PALND
surgery includes sufficient resection margins of the tumor and D3 dissection of the regional lymph nodes without PALND
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radical surgery with PALND
sufficient resection margins of the tumor, D3 dissection of the regional lymph nodes and para-aortic lymph node dissection from the bifurcation of iliac artery to the left renal vein via laparoscopic approach
Radical surgery without PALND
surgery includes sufficient resection margins of the tumor and D3 dissection of the regional lymph nodes without PALND
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG PS 0-1
* histologically confirmed left-sided colon and rectal carcinoma
* synchronous para-aortic lymph node metastases confirmed by PET-CT, and located below the level of renal veins and above the bifurcation of iliac artery
* patients potential to receive surgery and achieve no evidence of disease (NED)
* able to tolerate surgery
* providing written informed consent
Exclusion Criteria
* history of other malignant tumor
* coupled with severe systematic diseases (recent myocardial infarction, cardiomyopathy, or acute pulmonary infection)
* emergency surgery
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qilu Hospital of Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qilu Hospital of Shandong University
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xiang Zhang
Role: primary
Yanlei Wang
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
V123456
Identifier Type: -
Identifier Source: org_study_id